Altered megakaryocyte-platelet-haemostatic axis in patients with acute stroke

Platelet function is accentuated in acute ischaemic stroke (IS) and may also be altered in haemorrhagic stroke. Whether these changes are a direct reaction to the stroke or are secondary to changes in megakaryocytes (MKs) is unknown. To determine whether MKs are altered in acute stroke we studied 24 patients (18 with ischaemic stroke, six with haemorrhagic stroke) within 3 days of symptom onset, and 14 matched controls. MK ploidy (DNA content, N ), size (forward scatter, FSC, arbitrary units), granularity (side scatter, SSC, arbitrary units) and glycoprotein (GP) IIIa expression (arbitrary units) were assessed by flow cytometry. Platelet size (MPV, fl), platelet count (PC, 2 109/l), circulating reticulated platelets (%), and cutaneous bleeding time (s) were also measured. MK ploidy 22.5 (2.7) vs. 20.6 (1.7) (2 p = 0.014); FSC 629 (51) vs. 594 (41) (2 p = 0.025); and SSC 843 (88) vs. 776 (76) (2 p = 0.020) were each increased, whereas bleeding time 318 (102) vs. 401 (94) (2 p = 0.050) was decreased in patients with acute stroke as compared with controls. Trends to increased MK GP IIIa expression and reticulated platelets were also apparent. In a post hoc analysis, the increase in MK ploidy was most prominent in patients with a prior history of hypertension. Ischaemic stroke was associated with non-significant increases in MK ploidy, size, and granularity. However, MK parameters were different in acute haemorrhagic stroke as compared with controls: MK ploidy 23.0 (1.8) vs. 20.6 (1.7) (2 p = 0.018); MK FSC 637 (21) vs. 594 (41) (2 p = 0.050); MK SSC 872 (41) vs. 776 (76) (2 p = 0.020), changes which could be related to the high prevalence of hypertension (83%) in this group. These results demonstrate that pro-thrombotic changes in the megakaryocyte-platelet-haemostatic axis (MPHA) are present in acute stroke. Although megakaryocyte changes are likely, in part, to be secondary to the stroke, they could also precede the stroke and therefore explain some of the increased platelet function observed in acute stroke.

[1]  P. Langhorne,et al.  Platelet size in stroke patients. , 1995, Stroke.

[2]  S. Matsumoto,et al.  Usefulness of the measurement of plasma beta-thromboglobulin (beta-TG) in cerebrovascular disease. , 1983, Stroke.

[3]  H. Tohgi,et al.  Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. , 1991, Stroke.

[4]  A. Blann,et al.  Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. , 1998, Platelets.

[5]  J. Weinberger,et al.  Mechanisms in Lacunar Infarction , 1992, Stroke.

[6]  P. Bath,et al.  Platelets and Megakaryocytes in Vascular Disease , 1996 .

[7]  M. Fisher,et al.  Increased excretion of immunoreactive thromboxane B2 in cerebral ischemia. , 1985, Stroke.

[8]  P. Bath,et al.  The Routine Measurement of Platelet Size Using Sodium Citrate Alone as the Anticoagulant , 1993, Thrombosis and Haemostasis.

[9]  C. Thompson,et al.  Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function , 1982, British journal of haematology.

[10]  C. Kessler,et al.  Circulating Platelets Show Increased Activation in Patients with Acute Cerebral Ischemia , 1999, Thrombosis and Haemostasis.

[11]  Y. Hong,et al.  Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  J. Bessman.  The relation of megakaryocyte ploidy to platelet volume , 1984, American journal of hematology.

[13]  P. Bath,et al.  Altered megakaryocyte–platelet haemostatic axis in hypercholesterolaemia , 2001, Platelets.

[14]  P. Bath,et al.  Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study , 2001, Platelets.

[15]  V. Haver,et al.  Functional fractionation of platelets. , 1981, The Journal of laboratory and clinical medicine.

[16]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[17]  C. Thompson,et al.  Arachidonic acid metabolism by platelets of differing size , 1983, British journal of haematology.

[18]  M. Osawa,et al.  Platelet function tests in thrombotic cerebrovascular disorders. , 1983, Stroke.

[19]  P. Bath,et al.  The Bleeding Time Is Inversely Related to Megakaryocyte Nuclear DNA Content and Size in Man , 1988, Thrombosis and Haemostasis.

[20]  M. Burr,et al.  Influence of platelet size on outcome after myocardial infarction , 1991, The Lancet.

[21]  P. Bath,et al.  The relationship between mean platelet volume, stroke subtype and clinical outcome. , 1998, Platelets.

[22]  P. Bath,et al.  Platelet size: measurement, physiology and vascular disease. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  D. Slater,et al.  Platelet Production in Myocardial Infarction and Sudden Cardiac Death , 1984, Thrombosis and Haemostasis.

[24]  P. Bath,et al.  Platelets and stroke , 1999, Vascular medicine.

[25]  G. Zhang,et al.  Platelet hyperfunction exists in both acute non-haemorrhagic and haemorrhagic stroke. , 1994, Thrombosis research.

[26]  P. Bath,et al.  The King's College Hospital Acute Stroke Unit , 1996, Journal of the Royal College of Physicians of London.